El contexto digital actual progresa a un ritmo acelerado, lo que incrementa las brechas de seguridad para que los ciberdelincuentes puedan ejecutar sus ataques. Ante esta situación, las empresas no quieren continuar con una actitud reactiva ante los incidentes informáticos. …
Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases including lymphoma and autoimmune conditions.
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership Read More »
The diabetes tech firm is preparing for the launch of new devices, including a tubeless insulin pump and a fully closed loop automated insulin delivery system.
MiniMed submits new patch pump for FDA clearance Read More »
The medical device maker grew revenue by double digits in its fiscal first quarter, following fourth-quarter growth of nearly 10%.
Medtronic kicks off its fiscal year on a high note Read More »
GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA’s recent approval for Moderna’s mRNA flu vaccine.
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality Read More »
The systems agreed to 10 years of state oversight and $600 million in investments as South Dakota-based Sanford moves into the Twin Cities.
Sanford-North Memorial deal closes after systems ink oversight agreement Read More »
The certification positions GE HealthCare to challenge Siemens Healthineers for the European market.
GE HealthCare secures CE mark for photon-counting CT device Read More »
After downsizing by 50% last year, Arsenal Biosciences is again laying off employees. This time, 99 people are getting cut as part of a strategic shift to focus the company’s R&D efforts on in vivo CAR T therapies.
ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T Read More »
Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases of immune effector cell-associated hemophagocytic syndrome. BMS, meanwhile, paused some CAR T trials after separately observing “transient and reversible inflammatory events” with its therapy.
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events Read More »
Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program, representing some 89% of the branded drug market.
9 midsize drugmakers climb aboard Trump’s MFN train Read More »
